Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Instead, he said, he met them on their front lawn, where he popped the girl’s joint back in. “It is a very easy thing to do, but it made a huge difference for them,” he said. Gulbransen has had to rethink how he runs his pediatric practice on Long Island since the coronavirus crisis started. “We’re in the heart of the storm,” said Gulbransen. His practice remains open and now also welcomes some non-pediatric patients who have had trouble being seen by a doctor. He said his practice has been physically rearranged to keep sick patients away from those who are well. Other recent adjustments include doing telemedicine, although he is unsure how insurance reimbursements will work with such consultations. He said he was worried about his pediatric patients picking up on their parents’ anxieties, as well as the health and financial welfare of his staff. “The anxiety level is palpable,” said Gulbransen. “But it’s a privilege,” he said, adding, “you’re here for your patients. You gotta push and do whatever it takes.”  New York state, the epicenter of the pandemic in the United States, had a coronavirus death toll exceeding 10,000 as of Tuesday, out of more than 28,000 across the country. The disease looks different in children than it tends to with adults, said Gulbransen. “We had a 6-week-old with COVID, and really (the infant had) no other symptom than a runny nose,” said Gulbransen. He has also treated “quite a few toddlers and plenty of schoolage children,” who were all doing well. Cases of the illness involving children are “dwarfed by adult cases, although some of the (child) cases can be quite severe,” according to Dr. Lorry Rubin, director of pediatric infectious diseases at Cohen Children’s Medical Center, part of the Northwell Health network. Sometimes previously healthy children, often adolescents, develop pneumonia “and that can be severe and possibly lead to them needing oxygen or ventilatory support,” Rubin said. Still, most pediatric COVID-19 patients do well. Rubin said he was aware of only one child who had died, who also had a terminal congenital illness. Among infants under 60 days old in whom COVID had been detected, “all of them have done quite well,” he added. “The frequency of pediatric illness requiring hospitalization is low,” Rubin said. “No question, it’s not as bad in children and less common than in adults.”  But with New York’s healthcare system at full throttle treating coronavirus patients, Gulbransen wants to take no risks. His motto is: “Whatever you do, don’t send someone from this office to the ER.”
Example Output: 'Don't go to the ER': how a New York pediatrician is dealing with the coronavirus outbreak.

Example Input: The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it’s understandable that they wouldn’t comment on it — and that’s why we’re rating this Not Applicable. But let’s be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug — even one from the FDA — will include some mention of cost in its message. This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven’t been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent. As noted above, tumor shrinkage doesn’t always lead to improvements in survival or quality of life. It is a surrogate endpoint — a substitute — for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the “Summary,” another larger study is underway to assess the drug’s impact on extending life and improving quality of life. The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are “immune-mediated.” We would have liked a bit more context on what this term means for patients. The release outlines that this is the very first clinical trial of this compound for safety and efficacy, and under which regulatory paths the drug was assessed, including “breakthrough therapy designation, priority review status and accelerated approval.” We’re giving this release the benefit of the doubt and rating it Satisfactory for its bare bones description of the trial (and since we already addressed the lack of long-term survival data in the “Benefits” section.) As it stands, the results from the small trial were preliminary and short-term and did not reflect long-term survival. We would have liked to see a reference or link to the completed trial where one could look at the results to assess independently or learn more about the outcomes. We think the release should have provided more data on the patient demographics, the treatment regimen (dosing amount and schedule) as well as the range in tumor reduction. There is no disease mongering. This release describes the approval of a new drug by a regulatory agency, but we’d still like to know who sponsored the study that’s the basis for the approval. It’s not enough to state who markets the drug. The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn’t stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn’t respond to initially is the usual treatment. The FDA’s approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn’t state this explicitly but it can be inferred.) A NYT article said the drug would be available in about two months. The release clearly states this product is first of its kind for this type of cancer. We found no unjustifiable language.
Example Output: FDA approves new, targeted treatment for bladder cancer

Example Input: The 60-year-old sports fan, a surgeon who started and sold two pharmaceutical companies for a combined $8.6 billion, told Reuters in an interview this week that he wants to use Anschutz concert tours and sports events, and his NFL team’s players, to encourage L.A. school children to adopt healthier lifestyles. “The NFL can do so much for this city,” said Soon-Shiong in an interview at his west Los Angeles office. “Kids really rally around sports and entertainment and it could be a major catalyst to demonstrate what you can do in life by living better.”  Soon-Shiong grew up in South Africa, where he became a doctor in his early 20s and treated tuberculosis victims. After moving to the United States and becoming a surgeon at UCLA, he developed innovative methods to treat diabetes and cancer patients. The sale of his two companies for $8.6 billion made him the wealthiest person in Los Angeles, according to Forbes magazine, although he still is not a household name in the city. Under his plan, players would serve as mentors, encouraging students to eat better and exercise more. The most sophisticated methods used to deal with sports injuries could be shared with local doctors. “It’s important to motivate students in middle and high school. That’s when you can help reduce diabetes and obesity that cause illness,” he said. “Maybe we can turn that illness to wellness.”  If he’s successful in L.A., Soon-Shiong said he intends to make it a national program. Sources say the billionaire is assembling a group of other Los Angeles business and civic leaders to buy AEG. Soon-Shiong did not discuss details of his bid. Sources also said his buyer group includes private equity firm Guggenheim Partners, which this spring led a group that bought the Los Angeles Dodgers baseball team for $2 billion. AEG, which is owned by Denver billionaire Phil Anschutz, said on September 19 it had hired Blackstone Advisory Partners to sell the company. It is expected to fetch $6 billion to $8 billion, according to investment bankers with knowledge of its assets. Separately, Los Angeles for years has wanted to bring back a professional football team, and Soon-Shiong acknowledged that he has met with the NFL to lay out his plan to buy a team. AEG owns the Los Angeles Kings pro hockey franchise, the L.A. Galaxy soccer club and a 20 percent stake in the Los Angeles Lakers basketball team. It owns or operates sports and entertainment arenas worldwide, including the Staples Center in Los Angeles, and promotes concerts and other live action events. Soon-Shiong’s family foundation has committed $1 billion to transform healthcare and intends to create a national health superhighway by which doctors can share biotech information and other data to improve diagnosis and care. His foundation gave $135 million to the Saint John’s Health Center in Santa Monica and $100 million to reopen Martin Luther King Hospital, which serves lower income patients in south Los Angeles. A basketball fan who played in pickup games until tearing his Achilles tendon three years ago, Soon-Shiong owns a 5 percent stake in the Lakers, and he said he has become friends with superstar Kobe Bryant and other players, whom he sees as role models for young fans. In March, he and his actress wife, Michelle Chan, endowed the Chan Soon-Shiong Center for Sports Science at Saint John’s, which will focus on sports medicine, physical therapy and stem cell research to help heal injuries. It works with sports medicine doctors, including the Kerlan-Jobe Orthopedic Clinic that treats the Kings, Lakers and L.A. Dodgers. Saint John’s announced the sports science center at a dinner honoring AEG president Tim Leiweke in March, six months before Soon-Shiong showed his interest in the conglomerate.
Example Output:
LA billionaire covets sports teams to promote health.